pillbase.ru

Kadcyla

Active substance: ado-trastuzumab emtansine

trastuzumab emtansine

Centralised EU authorisationActive

Marketing holder: Roche Registration GmbH

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Кадсила®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 160 мг, 160 мг (original in Russian, GRLS)
    ЛП-№(000832)-(РГ-RU)
    Ф.Хоффманн-Ля Рош Лтд
  • Кадсила®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 100 мг, 100 мг (original in Russian, GRLS)
    ЛП-002692
    Ф. Хоффманн-Ля Рош Лтд.
US 2
  • KADCYLA
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TRASTUZUMAB EMTANSINE 20 mg/mL
    50242-088
    Genentech, Inc.
  • KADCYLA
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TRASTUZUMAB EMTANSINE 20 mg/mL
    50242-087
    Genentech, Inc.
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-3967-7a54-85e3-179c4c60f586,01a120c5-108b-7e6d-9449-d1462535445f;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12091-b65e-7548-8e63-7955b57a6527,01a12096-00b1-78e7-af6d-3c37abbee332;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/002389
Registration status
Active
ATC code
L01FD03
Sources
  • product · EMA · EMEA/H/C/002389 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/002389 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/002389 · Verified 2026-10-09